ROCHE Commitment to national health

Roche isone ofthe first multinational pharmaceutical companiesto enter Zhangjiang Hi-Tech Park and establish a complete pharmaceutical value chain in China. It is the market leader in the key areas of anti-tumor, anti-virusandtransplantation.

Among Roche’s early development and product research team, more than 330 full-time scientists were engaged in drug research and development, 80percentof whom were Chinese. As of the end 2017, Roche R&DCenter (China) has produced more than 190 patent applications for invention, half of which have been licensed.It spends 863millionyuan to build Roche Innovation Center Shanghai, which will be dedicated into researching anddevelopinginnovativeanti-infectives anddrugs for immune system diseases andinflammationto satisfy patients in China and overseas.At present, Roche has 18products in China, covering 8 treatment areas.

China’sadherenceto the reform and opening-up policy and the government’s emphasis on the national health, especially its goal of “increasing overall five-year survival rate of cancerpatientsby 15percent”in the “Health China2030”have promptedRoche to regard Shanghai as the third largest global strategic center,apart fromBasel, Switzerlandand San Francisco, US, and put into practiceits commitment of long-term development in the Chinese market.